Efficacy and safety of icotinib as first-line therapy in patients with advanced non-small-cell lung cancer

BACKGROUND AND OBJECTIVE: Several clinical trials have proven that icotinib hydrochloride, a novel epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor, exhibits encouraging efficacy and tolerability in patients with advanced non-small-cell lung cancer (NSCLC) who failed previous chemot...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Yan-Wei, Zhang, Xiao-Man, Li, Shu-Ting, Lv, Meng, Yang, Jiao, Wang, Fan, Chen, Zhe-Ling, Wang, Bi-Yuan, Li, Pan, Chen, Ling, Yang, Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4771396/
https://www.ncbi.nlm.nih.gov/pubmed/26966381
http://dx.doi.org/10.2147/OTT.S98363

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4771396/
https://www.ncbi.nlm.nih.gov/pubmed/26966381
http://dx.doi.org/10.2147/OTT.S98363

Ejemplares similares